Inhibikase Therapeutics, Inc. · NASDAQ:IKT

Trails Edge Capital Partners, LP reported a 5.10% stake in Inhibikase Therapeutics, Inc. (Schedule 13G)

Event Dec 23, 2025 · Filed Dec 31, 2025

Trails Edge Capital Partners, LP reported a 5.10% stake in Inhibikase Therapeutics, Inc., 6,145,198 shares, as a passive investor on Dec 23, 2025. Filed Dec 31, 2025 (Schedule 13G).

Stake
5.10%
Shares
6,145,198
Intent
Passive
What changed
Crossed above 5%
Filed together
3 holders

The filing in full

HolderStakeShares
Trails Edge Capital Partners, LP5.10%6,145,198
Trails Edge Biotechnology Master Fund, LP5.10%6,145,198
Ortav Yehudai5.10%6,145,198

Source

View original at SEC

Related